GLYC News and Press, GlycoMimetics Inc. From 11/12/21

GlycoMimetics’ main AML trial is close to completion of enrollment. Uproleselan Phase 3 trial likely to build on prior positive data. Results from a National Cancer Institute trial could expand the label. For further details see: GlycoMimetics A Buy On Nearing Tri...

Are you making a list of penny stocks to watch before next week? Today we’re looking at four tech and biotech stocks turning heads in the stock market today. While there are plenty of hot trends to follow right now, things like the metaverse, DeFi, and, yes, even biotechnology are in...

Two poster presentations detailing preclinical studies conducted at MD Anderson Cancer Center will highlight data demonstrating the potential of the Company’s dual antagonist of CXCR4 and E-selectin GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that two abstr...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Harout Semerjian will present an overview of the company at the upcoming Stifel 2021 Virtual Healthcare Conference on Monday, November 15 and the Jefferies London Healthcare Conference on Wednesday, Novembe...

GlycoMimetics, Inc. (GLYC) Q3 2021 Earnings Conference Call November 02, 2021, 08:30 ET Company Participants Shari Annes - IR Harout Semerjian - CEO, President & Director Eric Feldman - SVP & Chief Medical Officer Brian Hahn - SVP & CFO Conference Call Participants Edward White - ...

Image source: The Motley Fool. GlycoMimetics, inc (NASDAQ: GLYC) Q3 2021 Earnings Call Nov 2, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: GlycoMimetics, inc (GLYC) Q3 2021 Earnings Call Transcript

GlycoMimetics (NASDAQ:GLYC): Q3 GAAP EPS of -$0.34. Revenue of $0.08M (-92.0% Y/Y) Press Release For further details see: GlycoMimetics reports Q3 results

Significant progress achieved for lead investigational drug candidate uproleselan: Robust enrollment momentum in the quarter indicates imminent completion of enrollment for Company-sponsored Phase 3 pivotal trial in patients with relapsed/refractory acute myeloid leukemia (A...

OTCQX:ACDVF,AHH,AME,APO,OTCQX:ARBKF,ARCB,ARNC,AROC,AVNS,BCC,BHC,BLD,BLMN,BP,CEIX,CEN,CMI,COP,CRSR,CTLT,DD,DEA,EL,EOLS,EPD,ESPR,ETN,ETRN,EXTR,FMS,OTCPK:FSNUF,GLDD,GLYC,GNRC,GPN,HEP,HSIC,IAA,IART,IDXX,IEP,INCY,INGR,IPGP,IT,KKR,KOPN,LCII,LDOS,LEA,LGIH,LPX,MGY,MIME,MLM,MMP,MPC,MPLX,MYGN,OTCQB:NLS...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Tuesday, November 2, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and ...